Advancement of E2F1 in Common Tumors

Cheng SHEN; Jue LI; Shuai CHANG; Guowei CHE

doi:10.3779/j.issn.1009-3419.2020.101.32

Chinese Journal of Lung Cancer (Oct 2020)

Advancement of E2F1 in Common Tumors

Cheng SHEN,
Jue LI,
Shuai CHANG,
Guowei CHE

Affiliations

Cheng SHEN: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
Jue LI: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
Shuai CHANG: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
Guowei CHE: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China

DOI: https://doi.org/10.3779/j.issn.1009-3419.2020.101.32
Journal volume & issue: Vol. 23, no. 10
pp. 921 – 926

Abstract

Read online

The cell cycle-related transcription factor E2F1 is a member of the cell cycle-related transcription factor E2F family, mainly involved in various cell processes including cell cycle progression, DNA repair, DNA replication, cell differentiation, proliferation, and apoptosis. E2F1 is highly expressed in a variety of tumor tissues and cells, and it plays a role as a cancer-promoting gene. The up-regulation of E2F1 expression is closely related to the occurrence, development, metastasis and prognosis of tumors. Therefore, E2F1 is expected to become a new target for cancer treatment. This article reviews the latest research progress of E2F1 in current common tumors.

Published in Chinese Journal of Lung Cancer

ISSN: 1009-3419 (Print); 1999-6187 (Online)
Publisher: Chinese Anti-Cancer Association; Chinese Antituberculosis Association
Country of publisher: China
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.lungca.org

About the journal

Abstract

Keywords